Patent · US Active

Selectively substituted quinoline compounds

US9428495B2 · kind B2 · utility

33Cited by

71References

32Claims

0Family size

Assignee

Eisai R&D Management Co., Ltd. · JP

Inventors

Eric Carlson · Merrimack, US
Hans Hansen · Somerville, US
Lynn Hawkins · Concord, US
Sally Ishizaka · Weston, US
Matthew Mackey · Melrose, US
Shawn Schiller · Haverhill, US
Chikako Ogawa · Basel, CH
Heather Davis · Haverhill, US
Atsushi Endo · Boston, US

Key dates

Filing date	Oct 14, 2014
Grant date	Aug 30, 2016
Priority date	—
Expiry date	Oct 21, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/07
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.